CLDF Title
Home | Contact Us | Bookmark
MASH HCC ALCOHOL LIVER DISEASE PEDIATRIC LIVER DISEASE
Embassy of Education
Webcasts Abstract Library LiverQ Academy National Conference Regional Conferences
 
Back  
 
Reuters Health Information (2006-02-06): Cyclosporine shows anti-HCV activity in vitro and in liver transplant recipients

Science

Cyclosporine shows anti-HCV activity in vitro and in liver transplant recipients

Last Updated: 2006-02-06 8:44:16 -0400 (Reuters Health)

NEW YORK (Reuters Health) - The immunosuppressive agent cyclosporine is active against hepatitis C virus (HCV) in vitro and its use can improve the chances of a sustained virologic response in HCV-infected liver transplant recipients, new research shows.

In previous studies, cyclosporine has shown activity against HIV, herpes simplex, and vaccinia viruses, according to the report in the January issue of Liver Transplantation. Now, Dr. Roberto J. Firbi, from the University of Florida in Gainesville, and colleagues evaluated the drug's ability to clear HCV in liver transplant recipients treated with interferon and ribavirin for 48 weeks after progressive histologic disease was identified.

The retrospective analysis involved 56 patients who were treated with a cyclosporine-based immunosuppressive regimen and 59 treated with one based on tacrolimus.

The sustained virologic response rate in the cyclosporine group was 46%, much higher than the 27% rate noted in the tacrolimus group (p = 0.03).

In vitro analysis showed that cyclosporine inhibited HCV replication in a dose-dependent fashion. Moreover, the mechanism involved is distinct from that used by interferon and an additive effect was seen when both drugs were given together.

"HCV infection is of major concern after liver transplantation due to universal recurrence, more rapid fibrosis progression, and potential graft failure," the authors state. The present findings suggest that cyclosporine is better than tacrolimus at halting HCV replication, but confirmation in randomized controlled trials is needed.

Liver Transpl 2006;12:51-57.

 
 
 
 

Subscribe

Be the first to know about our latest upcoming programs and events!

CLDF

Follow us

The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2025 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.